Overview

Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The goals of this open-label Phase Ia study are to evaluate the Pharmacokinetics (PK) profiles of new novel single-dose Ondansetron Pulsatile Release (Ond-PR) formulations in normal healthy volunteers. After this initial phase, the investigators will follow with the Phase Ib study to determine Pharmacokinetic/Pharmacodynamic (PK/PD), safety, and tolerability interactions following simultaneous administration of these ondansetron formulations with a 10 mg Methylphenidate Immediate Release (MPh-IR) tablet in normal healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Tong Lee
Treatments:
Methylphenidate
Ondansetron